序号 |
标题 |
次数 |
作者 |
发布时间 |
84511 |
3,6-双胍基-1,2,4,5-四嗪三硝基均苯三酚盐 |
93 |
WYQ |
2024-11-27 |
84512 |
DOTA-Z(PDGFRβ)-tri探针 ,螯合剂DOTA修饰PDGFRβ三聚亲和体ZPDGFRβ-tri |
97 |
kx |
2024-11-27 |
84513 |
3,6-双胍基-1,2,4,5-四嗪三硝基间苯二酚盐 |
89 |
WYQ |
2024-11-27 |
84514 |
3,6-双胍基-1,2,4,5-四嗪三硝基苯酚盐(DGTZ-TNP盐) |
109 |
WYQ |
2024-11-27 |
84515 |
6-氨基胍基-1,2,4,5-四嗪-3-酮(AGTzO) |
98 |
WYQ |
2024-11-27 |
84516 |
DOTA-NAPamide trifluoroacetate;935886-72-9 |
82 |
zcy |
2024-11-27 |
84517 |
5,7-二硝基苯并1,2,3,4-四嗪-1,3-二氧化物(DNBTDO) |
110 |
WYQ |
2024-11-27 |
84518 |
DOTA-Palm-3PRGD2, DOTA-Palm修饰3PRGD2药物 |
106 |
kx |
2024-11-27 |
84519 |
7-硝基苯并1,2,3,4-四嗪-1,3-二氧化物(7-NBTDO) |
102 |
WYQ |
2024-11-27 |
84520 |
DOTA-FAPI-04 ,DOTA偶联成纤维细胞活化蛋白抑制剂 |
205 |
kx |
2024-11-27 |
84521 |
446061-19-4 DOTA-p-NH2-Bn-(COOt-Bu)4 DOTA-P-苯-氨基-四叔丁酯 |
102 |
zcy |
2024-11-27 |
84522 |
5-硝基苯并1,2,3,4-四嗪-1,3-二氧化物(5-NBTDO) |
110 |
WYQ |
2024-11-27 |
84523 |
DOTA octreotide,大环配体奥曲肽 |
100 |
zyl |
2024-11-27 |
84524 |
3,6-二胍基-1,2,4,5-四嗪(DGTZ) |
103 |
WYQ |
2024-11-27 |
84525 |
gallium Ga 68-DOTATATE , 镓68偶联DOTATATE螯合物 |
169 |
kx |
2024-11-27 |
84526 |
3,6-二叠氮基-1,2,4,5-四嗪(DIAT) |
103 |
WYQ |
2024-11-27 |
84527 |
DOTA N-hydroxysulfosuccinimide ester 170908-81-3 DOTA-活性酯 |
95 |
zcy |
2024-11-27 |
84528 |
四嗪类高氮含能化合物 |
214 |
WYQ |
2024-11-27 |
84529 |
p-SCN-Bn-DOTA , 2-[(4-异硫氰基苯基)甲基]-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 |
92 |
kx |
2024-11-27 |
84530 |
咪唑并四嗪(Imidazopyrazine) |
96 |
WYQ |
2024-11-27 |
84531 |
二聚体多肽,250612-06-7 |
106 |
zyl |
2024-11-27 |
84532 |
DOTA-(t-Butyl)3-PEG5-azide 点击化学试剂 |
105 |
zcy |
2024-11-27 |
84533 |
降冰片烯衍生物(C16-NCA) |
186 |
WYQ |
2024-11-27 |
84534 |
DOTA-CS微球 ,壳聚糖微球上接枝螯合剂1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA) |
84 |
kx |
2024-11-27 |
84535 |
1, 4, 7,10-四氮杂环十二烷-1, 4, 7-三(乙酸)-10-(2-硫乙基)乙酰胺 |
88 |
zcy |
2024-11-27 |
84536 |
3,6-二肼基-1,2,4,5-四嗪(DHT) |
121 |
WYQ |
2024-11-27 |
84537 |
DBCO-SS-PEG-DOTA 二苯并环辛炔-聚乙二醇之四氮杂环十二烷 |
90 |
zyl |
2024-11-27 |
84538 |
3-叠氮基-6-(3,5-二甲基吡唑)-1,2,4,5-四嗪(IADMPT) |
107 |
WYQ |
2024-11-27 |
84539 |
3-肼基-6-(3,5-二甲基吡唑)-1,2,4,5-四嗪(HDMP |
111 |
WYQ |
2024-11-27 |
84540 |
p-NH2-Bn-DOTA(B-200);181065-46-3;基于NOTADOTA定制和偶联 |
81 |
zcy |
2024-11-27 |
84541 |
DOTA-CSar-1 ,DOTA-胆酰肌氨酸 |
141 |
kx |
2024-11-27 |
84542 |
DOTA-MeTz,1610950-41-8,DOTA-甲基四嗪 |
94 |
zyl |
2024-11-27 |
84543 |
四嗪Tetrazine (C18-Tz) |
259 |
WYQ |
2024-11-27 |
84544 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪羟胺盐(TATTN·NH3OH) |
122 |
WYQ |
2024-11-27 |
84545 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪铵盐(TATTN·NH4) |
108 |
WYQ |
2024-11-27 |
84546 |
HA-ASP-CYS-Gd-DOTA ,透明质酸为载体的靶向肿瘤的大分子T1钆基造影剂 |
125 |
kx |
2024-11-27 |
84547 |
CAS:3001301-68-1;DOTA(单酰胺)-OH;DOTA(Monoamides)-OH |
95 |
zcy |
2024-11-27 |
84548 |
DOTA NOC acetate,619300-53-7 |
123 |
zyl |
2024-11-27 |
84549 |
DOTA-SC691-6KL,DOTA偶联卤素取代物 |
105 |
kx |
2024-11-27 |
84550 |
不对称炔丙基取代(+)-Citralis-Propargyl |
97 |
WYQ |
2024-11-27 |
84551 |
不对称炔丙基取代(+)-Phenoxanol-Propargyl |
69 |
WYQ |
2024-11-27 |
84552 |
CAS:250612-06-7;DOTA-RGD探针二聚体;dota-glu[cyclo(arg-gly-asp-d-phe-lys)]2 |
84 |
zcy |
2024-11-27 |
84553 |
不对称炔丙基取代(-)-AMG 837 |
85 |
WYQ |
2024-11-27 |
84554 |
PEG-G5.NH2-FITC-DOTA(Gd)-Monalizumab/IPH4301纳米探针 |
84 |
kx |
2024-11-27 |
84555 |
不对称炔丙基取代(+)-Phenoxanol-Propargyl |
76 |
WYQ |
2024-11-27 |